Classification of Liver Disease
Liver disease is classified primarily by etiology (cause), followed by severity grading (degree of inflammation/activity) and staging (extent of fibrosis/cirrhosis), with modern nomenclature emphasizing metabolic dysfunction-associated conditions. 1
Primary Classification Framework
By Etiology (Cause)
The fundamental classification system organizes liver disease by underlying cause 1, 2:
Metabolic/Steatotic Liver Diseases:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) - replaces the outdated term "NAFLD" to better reflect metabolic causes 3
- Metabolic dysfunction-associated steatohepatitis (MASH) - replaces "NASH," indicating histologically confirmed metabolic steatohepatitis 3
- MetALD - MASLD with moderate regular alcohol consumption (a newly defined entity) 3
Viral Hepatitis:
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Hepatitis D (HDV)
- Other viral hepatitis 1
Alcohol-Related Liver Disease (ALD):
- Definition unchanged: alcohol consumption >50-60g/day 3
Other Specific Etiologies:
- Primary sclerosing cholangitis
- Primary biliary cirrhosis
- Autoimmune hepatitis
- Drug-induced liver injury
- Wilson disease
- Hemochromatosis 1
By Disease Severity and Stage
After establishing etiology, liver disease is further characterized by:
Grading (Activity/Inflammation):
- Assesses the degree of ongoing hepatocellular injury and inflammation
- Uses semiquantitative scoring systems for research and treatment monitoring 2
Staging (Fibrosis Progression):
- F0: No fibrosis
- F1: Portal fibrosis without septa
- F2: Portal fibrosis with few septa (significant fibrosis threshold)
- F3: Numerous septa without cirrhosis
- F4: Cirrhosis 4
Clinical Progression Classification
Compensated vs. Decompensated Cirrhosis:
The progression follows: chronic hepatitis → hepatic fibrosis → compensated cirrhosis → decompensated cirrhosis 1
Decompensated cirrhosis is defined by development of:
- Portal hypertension complications
- Gastrointestinal hemorrhage
- Refractory ascites
- Hepatic encephalopathy
- Hepatorenal syndrome 1
Acute-on-Chronic Liver Failure (ACLF) Classification
A newer classification approach divides ACLF by organ failure pattern 5:
Type I ACLF (86.9% of cases):
- Liver failure only within first week (total bilirubin ≥5 mg/dL, INR ≥1.5)
- Primarily occurs in non-cirrhotic chronic liver disease (34.3%) or compensated cirrhosis (48.6%)
- 28-day mortality: 15.8%; 90-day mortality: 24.9%
Type II ACLF (13.1% of cases):
- Liver failure plus concurrent extrahepatic organ failure
- Predominantly in cirrhotic patients (73%)
- 28-day mortality: 43.2%; 90-day mortality: 52.3%
- Significantly worse prognosis 5
Diagnostic Approach for Staging
Non-invasive assessment is preferred over liver biopsy for longitudinal monitoring 1:
For Significant Fibrosis (≥F2):
- Transient elastography (TE) cut-offs: 7.0-8.8 kPa depending on etiology
- AUROC values: 0.79-0.92 4
For Cirrhosis (F4):
- TE cut-offs: 9.7-22.7 kPa (varies by etiology: HBV 9.7 kPa, ALD 22.7 kPa)
- AUROC values: 0.80-0.99
- Better at ruling out than ruling in cirrhosis (NPV 96%, PPV 74%) 4
Key Clinical Pitfalls
Common Classification Errors:
- Using outdated terminology (NAFLD/NASH instead of MASLD/MASH) - the 2023 nomenclature reform reflects better understanding of metabolic pathophysiology 3
- Failing to distinguish compensated from decompensated cirrhosis - this distinction fundamentally changes prognosis and management 1
- Overlooking MetALD as a distinct entity - patients with MASLD and moderate alcohol use require different counseling 3
- Relying solely on imaging morphology without elastography - conventional ultrasound, CT, and MRI are inadequate for intermediate fibrosis stages 4, 1
Critical Point: Liver biopsy remains the gold standard for diagnosis but is costly, subject to sampling error, and poorly accepted for monitoring. Non-invasive methods (elastography, serum markers) should be prioritized for serial assessment 1.